Gynecomastia, or excessive male breast development, has an incidence of 32 to 65 percent in the male population. This condition has important physical and psychological impacts. Advances in elucidating the pathophysiology of gynecomastia have been made, though understanding remains limited. Recommendations for evaluation and workup have varied and are often arbitrary. A diagnostic algorithm is suggested, with emphasis on a comprehensive history, physical examination, and minimizing unnecessary diagnostic testing. Medical management has had limited success; surgical therapy, primarily through excisional techniques, has been the accepted standard. Although effective, excisional techniques subject patients to large, visible scars. Ultrasound-assisted liposuction has recently emerged as a safe and effective method for the treatment of gynecomastia. It is particularly efficient in the removal of the dense, fibrous male breast tissue while offering advantages in minimal external scarring. A new system of classification and graduated treatment is proposed, based on glandular versus fibrous hypertrophy and degree of breast ptosis (skin excess). The authors' series of 61 patients with gynecomastia from 1987 to 2000 at the University of Texas Southwestern Department of Plastic Surgery demonstrated an overall success rate of 86.9 percent using suction-assisted lipectomy (1987 to 1997) and ultrasound-assisted liposuction (1997 to 2000) . The authors have found ultrasound-assisted liposuction to be effective in treating most grades of gynecomastia. Excisional techniques are reserved for severe gynecomastia with significant skin excess after attempted ultrasound-assisted liposuction. (Plast. Reconstr. Surg. 111: 909, 2003.) Gynecomastia is defined as benign, excessive breast development in male individuals. Initially thought to be a rare condition, with a reported incidence of 8 in 100,000 during World War II, 1 more recent studies have reported an overall incidence of 32 to 36 percent, 2, 3 even as high as 40 percent of men in an autopsy series 4 and 64.6 percent in adolescent boys. 5 The incidence of bilateral involvement also varies in the literature. Bilateral disease occurs in 25 to 75 percent of patients. 6, 7 This wide variation likely stems from an increased appreciation of the psychological, physical, and social impact of the condition. It underscores the lack of a clear and standardized definition within the plastic surgery and medical literature.
The etiology of gynecomastia is multifactorial, but in many cases, an identifiable cause is elusive. Recent investigations have demonstrated pathophysiologic mechanisms to involve either a relative or absolute excess of estrogens, a decrease of circulating androgens, or a defect in androgen receptors. This has been the basis for recent attempts at medical therapy for gynecomastia. However, surgical removal of the hypertrophic breast tissue remains the accepted standard in treatment.
Surgical management, until recently, mostly consisted of excisional techniques. Standard suction-assisted lipectomy had an adjunctive role, as described by Teimourian and Pearlman in 1983. 8 Suction-assisted lipectomy as a primary mode of treatment had been advocated by others. 9, 10 Ultrasound-assisted liposuction, with known mechanical advantages in addressing dense, fibrous lipodystrophy, has recently emerged as the preferred technique for management of gynecomastia. agnosis, and our preferences in the treatment of gynecomastia. Based on our experience at the University of Texas Southwestern Medical Center, Department of Plastic and Reconstructive Surgery, over the past 14 years, we propose a new classification system for gynecomastia incorporating the emerging role of ultrasoundassisted liposuction as a safe and effective method for treatment.
ETIOLOGY
Gynecomastia has many identifiable causes, though most cases are idiopathic. Recent studies have shown strong evidence for the estrogen-stimulating effects of breast tissue development and support for an inhibitory androgenic effect. Decreases in the androgen-to-estrogen ratio have also been associated with development of gynecomastia. No clear etiologic classification has been suggested based on hormonal influences solely. Instead, most physicians accept an arbitrary classification based on physiologic, pathologic, pharmacologic, and idiopathic causes (Table I) . Idiopathic causes (25 percent) are the most common. 6 Physiologic gynecomastia can be further subdivided into neonatal, pubertal, and elderly periods. Circulating maternal estrogens transferred by the placental-fetal circulation are thought to contribute to excessive development of breast tissue in neonates. Because this is usually a self-limited process lasting weeks to months, treatment is rarely indicated. Adolescent boys (up to 65 percent) often exhibit varying degrees of gynecomastia, which usually resolves over several months to years. 5 The degree of breast enlargement can be so minor as to escape recognition unless clinically palpated. Relative excess of plasma estradiol compared with testosterone is implicated in the pathogenesis of pubertal gynecomastia. 12, 13 Older men (beginning at age 65) will often develop breast enlargement as plasma testosterone levels decline and peripheral conversion of testosterone to estrogen (peripheral aromatization) occurs, thus effectively increasing the plasma estrogen-to-androgen ratio. 6 Pathologic gynecomastia occurs as a result of various metabolic disorders (alcoholic cirrhosis, refeeding after a starvation state, feminizing adrenal tumors), endocrine disorders (hyperthyroidism, adrenal cortical hyperplasia, hypothyroidism), acquired hypogonadal states (orchitis, testicular trauma, granulomatous disease, renal failure, alcoholism, myotonic dystrophy), congenital hypogonadal states (Klinefelter syndrome, congenital anorchia, androgen resistance), and increased estrogen states (bronchogenic carcinoma, true hermaphroditism, testicular tumors). 6,14 -16 The specific pathophysiologies are beyond the scope of this discussion.
Pharmacologic gynecomastia occurs by several mechanisms, including increased direct estrogenic activity, increased secretion of estrogen, decreased testosterone synthesis, and decreased androgen sensitivity. There are also many drugs with poorly understood mecha- nisms that are associated with gynecomastia 6, 17, 18 (Table II) . Histologically, Bannayan and Hajdu 19 identified the following three patterns with varying degrees of stromal and ductal proliferation: florid, intermediate, and fibrous types. The florid pattern shows increased numbers of budding ducts in a highly cellular fibroblastic stroma. Fibrous type has extensive stromal fibrosis with minimal ductal proliferation. Intermediate type demonstrates overlapping of the fibrous and florid histologic patterns. Most observers agree that these patterns represent a transition related to duration of gynecomastia and its symptoms, with florid type seen usually in gynecomastia of less than 4 months' duration and fibrous type seen in gynecomastia lasting longer than 1 year. 19 
ASSOCIATED RISKS OF MALE BREAST CANCER
One percent of all breast cancer occurs in men. Patients with Klinefelter syndrome, however, have up to a 60 times greater risk of developing breast cancer, and the incidence is approximately 1:400 to 1:1000. 20 Many studies reviewing male subjects with gynecomastia have demonstrated no increased risk for breast cancer as compared with the normal male population. 6 Thus, in all non-Klinefelter patients, it is reasonable to treat gynecomastia surgically with both liposuction and excisional techniques without adding considerable morbidity of delayed detection of male breast cancer.
In those patients in whom hypogonadism is suspected, Klinefelter syndrome must be ruled out because this will ultimately impact treatment. Because of the oncologic risk in these patients, excisional techniques are preferred in this scenario.
DIAGNOSIS
Clinical evaluation of patients with gynecomastia is paramount. However, further workup is rarely indicated. History elicited should include age, duration and onset of breast enlargement, symptoms of pain or tenderness, medications and recreational drug use, and psychological and social effects. A review of systems should involve signs/symptoms of hepatic disease, hyperthyroidism or hypothyroidism, recent weight gain or loss, adrenal disease, alcoholism, renal failure, and malignancies.
Physical examination of the breasts should involve assessment for glandular or fat predominance (by the pinch test), degree of glandular ptosis, skin excess, nodules/masses, and nipple abnormalities or discharge. Glandular or parenchymal tissue is characterized by rubbery breast tissue that is mobile and extends from a subareolar, centric position. Suspicious nodules or masses may have abnormal firmness, overlying skin ulceration, eccentric location, or abnormal nipple discharge. The normal male breast is typically flat with some fullness around the nipple-areola complex. The nipple-areola complex is normally 2 to 4 cm in diameter (average, 2.8 cm) 21, 22 and located over the fourth intercostal space. Nipple to sternal notch distance is, on average, 20 cm.
23 A muscular male chest may exhibit superior fullness with a transition to a flat inferior chest near the inframammary fold. Completion of the physical examination should in particular assess for testicular enlargement/atrophy and asymmetry, thyromegaly, hepatomegaly, pulmonary abnormalities, and abdominal masses.
Additional diagnostic testing should be individualized to address abnormalities identified in the history or physical examination. Individualized workups have also been suggested depending on age at the time of development of gynecomastia (Table III) . These considerations are important, but arbitrary use of "screening" tests or laboratory data is not recommended. Rarely is an extensive workup indicated, and often it will not affect treatment. Certain clinical findings, however, should prompt further evaluation. In the scenario of a young patient (especially prepubertal) with a negative history and bilateral gynecomastia, a testicular ultrasound in conjunction with a careful testicular examination has been found to be cost-effective. The incidence of a functional endocrine tumor in this group is significant. 24 Physical examination findings of feminization, including small testicular size (Ͻ 3 cm in length or 8 cc in volume), lack of male hair distribution, or a eunuchoid body habitus, suggest a possible feminizing tumor. Endocrine testing in this situation (serum testosterone, luteinizing hormone, estradiol, and the sulfate salt of dehydroepiandrosterone) is appropriate. If feminizing characteristics are found in association with a marfanoid body habitus, a karyotype and endocrine referral is indicated to rule out Klinefelter syndrome. 7 A patient should consider proceeding with surgical management once diagnosis of gynecomastia is established of nonphysiologic causes or of duration greater than approximately 12 months, because hypertrophic breast tissue beyond this stage usually becomes irreversibly fibrotic. 19 An algorithm for the diagnosis and directed treatment of gynecomastia is suggested ( Fig. 1 and Table IV). Nonsurgical management has involved correction of underlying causes, medications to regulate hormonal imbalances, and irradiation. Medical therapy with testosterone, antiestrogens (clomiphene, tamoxifen), and danazol has had only limited success. 6, 25 Gynecomastia of long duration is unlikely to regress spontaneously and will often progress to irreversible dense fibrosis and hyalinization despite medical therapy. Withdrawal of an offending drug, correction of a systemic disorder, or the natural course of physiologic gynecomastia often results in spontaneous regression of gynecomastia; however, correction of an underlying disorder may not be effective in treating gynecomastia, especially if the duration of disease is lengthy and fibrosis of breast tissue has already occurred. 26 Thus, surgery remains the accepted standard for management. The evolution of surgical techniques for gynecomastia can be traced in the literature: 1. Semicircular intra-areolar incision 27 resection of cone-shaped mass of breast tissue centrally with peripheral taper; reapproximation of fat beneath areola 2. Inverted omega intra-areolar incision 28 improved exposure to undersurface of areola 3. Horizontal transareolar/intra-areolar incision 29 10 -used to evacuate both adipose tissue and dense parenchymal tissue in the breast, citing use of smaller 2.4-mm cannula as critical component for effective evacuation of the dense parenchyma 17. Suction-assisted lipectomy 9 -useful in selected patients with predominantly fatty breasts and well-located nipple/areola 18. Suction-assisted lipectomy 41, 42 19. Suction-assisted lipectomy 43 -axillary approach for suction lipectomy 20. Eccentric skin resection and pursestring closure 44 21. Endoscopic transaxillary approach 45 22. Circumareolar skin and suction-assisted lipectomy 46 -technique described for patients with severe gynecomastia. 23. Ultrasound-assisted liposuction 11 -technique reviewed, successful use in all three grades of gynecomastia 24. Pinwheel technique 47 25. Ultrasound-assisted liposuction 48 -excellent results using ultrasound-assisted liposuction for most types of gynecomastia As mentioned, suction-assisted lipectomy has been used to treat gynecomastia primarily or adjunctively with some success; limitations were encountered with severe cases or in breasts with primarily fibrous tissues. Ultrasound-assisted liposuction has extended the role of lipoplasty in the management of gynecomastia. Zocchi 49 first described the technique of using ultrasonic energy transmitted by means of excited piezoelectric crystals placed on terminal ends of suction cannulas to emulsify fat while preserving adjacent nervous, vas- Rohrich et al. 50 -53 have further refined the ultrasound-assisted liposuction technique, incorporating a three-stage process of subcutaneous infiltration of a wetting solution, followed by ultrasound-assisted liposuction and completed by evacuation and final contouring by suction-assisted lipectomy. Endpoints for ultrasound-assisted liposuction (time and loss of resistance) differ from those for standard suction-assisted lipectomy (pinch and contour) but now provide parameters for safe and efficient lipectomy.
Ultrasound-assisted liposuction has several advantages over suction-assisted lipectomy in the treatment of gynecomastia. Several studies have confirmed the selective emulsification of fat leaving higher density structures, such as fibroconnective tissue, relatively undamaged. This allows for more efficient fat removal in areas that have higher densities of fibroconnective tissue, such as the male breast. At higher energy settings, ultrasound-assisted liposuction is effective in removal of the denser, fibrotic parenchymal tissue that suction-assisted lipectomy is inefficient in removing. Also, ultrasound-assisted liposuction performed in the appropriate subdermal plane affects the dermis, allowing for skin retraction in the postoperative healing period. Further advantages of ultrasound-assisted liposuction include the reduced physical demand for large-volume liposuction of the breast, allowing the surgeon improved attention to precise contouring. 6, 23, 54, 55 Previous clinical classification systems, as suggested by Simon et al. 33 and Cohen et al., 6 offered excellent guidelines for graduated management of gynecomastia based on degrees of lipodystrophy and skin excess. Most recommended techniques were excisional with suction-assisted lipectomy offered as an adjunctive measure for final contouring. We offer a new classification system for gynecomastia and the preferred treatment at each grade, incorporating the role of ultrasound-assisted liposuction as a superior method for safe and effective removal of male breast tissue, based on our experience with 61 patients evaluated and treated for gynecomastia from 1987 to 2000 (Table IV) . Our classification of gynecomastia is based on the amount and character of breast hypertrophy and the degree of ptosis. Preoperative and postoperative examples are shown to demonstrate the efficacy of ultrasound-assisted liposuction. Grade I patients (Fig. 2) have minimal hypertrophy (Ͻ 250 g of breast tissue), and grade II patients (Figs. 3 and 4) have moderate hypertrophy (between 250 and 500 g of breast tissue). These grades can be further subdivided into IA and IIA for primarily fatty breast tissue and IB and IIB for primarily fibrous breast tissue. Grade III and IV patients (Figs. 5 and 6 ) have severe hypertrophy (Ͼ 500 g of breast tissue) but are distinct because of a greater degree of ptosis. Grade III gynecomastia patients exhibit grade 1 ptosis, and grade IV gynecomastia patients show grade 2 or 3 ptosis.
Suction-assisted lipectomy can be used in grade IA and grade IIA gynecomastia with success. However, it is a suboptimal treatment for more severe gynecomastia (grade III and IV) and for any gynecomastia with primarily fibrous tissue.
Ultrasound-assisted liposuction is effective in all grades of gynecomastia. Usually, no further treatment is needed in grade I or II gynecomastia and, often, single ultrasound-assisted liposuction treatment is all that is necessary for grades III and IV, especially in those with mild ptosis and good skin quality. If removal of redundant skin and/or resistant lipodystrophy is still required after ultrasound-assisted liposuction, a staged excision is delayed for 6 to 9 months to allow for maximal skin retraction and healing, thus potentially allowing downstaging of the magnitude of the excisional technique (and therefore minimizing scarring).
ULTRASOUND-ASSISTED LIPOSUCTION TECHNIQUE
After thorough evaluation of a patient, including a detailed history and physical examination, markings are made to outline boundaries of treatment. The inframammary fold should be marked preoperatively with the patient sitting or standing. Adherent zones in the upper outer quadrants, as the breast retreats into axillary tissue, should be suctioned with caution (Fig. 7) . Patients receive general anesthesia and are positioned supine with arms abducted. Incisions (3 to 4 mm) are made with a no. 11 scalpel in the lateral inframammary folds bilaterally for optimal access to the dense breast parenchyma. This route also provides superior access to obliterate the inframammary fold and to suction the medial chest. nant hand guiding the ultrasound-assisted liposuction cannula through the subdermal layer. Liposuction of the subdermal layer is not a traditional level of treatment in ultrasound-assisted liposuction, but it is particularly important in addressing the dense fibrous tissue of gynecomastia and allowing for maximal skin retraction. The periphery is treated for feathering and contouring. Disruption of the inframammary fold is essential in achieving a more gradual transition of the breast to the abdomen, which is characteristic in men (as opposed to the distinct demarcation of the inframammary fold in women). The adherent zone should be suctioned minimally, if at all (only for contouring), and extreme caution should be exercised. Suction-assisted lipectomy is performed in standard fashion using a 3. taken to avoid overcontouring of the area overlying the upper lateral pectoralis major muscle.
In the situation of small, residual, dense subareolar tissue, it is reasonable to excise this after ultrasound-assisted liposuction through a periareolar incision. Our preference is not to address skin excess at the initial operation. We recommend allowing for maximal skin retraction after ultrasound-assisted liposuction before staged skin excision, if required. After evacuation is complete, incisions are closed with 5-0 fast absorbing plain gut. The chest wall is dressed with a double layer Topifoam, and a compressive vest is to be worn by the patient for 4 weeks continuously followed by 4 weeks at nighttime only.
Our experience has demonstrated that staged excision can be accomplished through a periareolar approach in most cases. An inferior 180-degree incision through the areolar margin is used to gain access to any residual subareolar tissue. Excision through extensive breast mound incisions has rarely been required. A series of 60 patients treated by ultrasoundassisted liposuction was reported by Gingrass and Shermak. 48 No major complications, hematomas, or episodes of skin necrosis have (Table V) . Eight patients, four with grade III disease and four with grade IV gynecomastia, required staged excision of remaining breast tissue and skin (6 to 9 months after ultrasound-assisted liposuction) to optimize results.
DISCUSSION
Gynecomastia is a benign condition that afflicts as many as 65 percent of male individuals. Advances have been made in elucidating its causes and pathophysiologic mechanisms.
However, most cases remain idiopathic. Medical therapies have largely been ineffective. Historically, surgical management of gynecomastia has involved primarily excisional techniques with suction-assisted lipectomy used adjunctively for contouring. Most excisional techniques are effective in achieving reduction of glandular and fibrotic breast tissue. However, these techniques can subject the patient to large, visible scars on the chest wall. 56 More recently, ultrasound-assisted liposuction has emerged as the preferred surgical technique for most cases of gynecomastia, providing the advantages of minimal scarring and efficient removal of both glandular and fibrotic breast tissue. The precise effects of ultrasoundassisted liposuction on skin contraction are not yet known, although our experience has shown a considerable amount of retraction, particularly in patients with grade III and IV gynecomastia, depending on the patients age and skin elasticity. The degree of ptosis or skin excess has not altered our treatment algorithm with regard to ultrasound-assisted liposuction. We recommend that ultrasound-assisted liposuction be used first to allow for maximal skin retraction. If residual skin excess or breast tissue exists 6 to 9 months later, we recommend considering excisional techniques at that time. Our experience has demonstrated that more than 85 percent of patients treated with ultrasound-assisted liposuction did not require extensive skin incisions for removal of the remaining tissue.
A new classification system is suggested adopting ultrasound-assisted liposuction as a safe and effective treatment for most grades of gynecomastia. Specific treatment is directed by grade, with the goal of achieving a normal-appearing male chest while minimizing residual deformity and avoiding excessive scars.
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